Hudson Bay Capital Management
SABS icon

Hudson Bay Capital Management’s SAB Biotherapeutics SABS Stock Holding History

Hudson Bay Capital Management’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,100
Closed -$61.7K – 1648
2026
Q1 		$61.7K Buy
+16,100
New +$64.2K ﹤0.01% 1228
2021
Q4 		– Sell
-50,000
Closed -$5.04M – 1190
2021
Q3 		$5.04M Hold
50,000
– – 0.07% 325
2021
Q2 		$4.99M Hold
50,000
– – 0.06% 336
2021
Q1 		$4.91M Buy
+50,000
New +$5M 0.06% 296

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Hudson Bay Capital Management's SABS Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of SAB Biotherapeutics (SABS) in Q2 2026, closing a stake of 16,100 shares — an estimated $61.7K sold.

Hudson Bay Capital Management first reported a position in SABS in Q1 2021 and held it in 4 quarters. The position peaked at $5.04M in Q3 2021. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining SAB Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 16,100 SAB Biotherapeutics shares in Q2 2026, an estimated $61.7K.
  • Hudson Bay Capital Management first reported a position in SAB Biotherapeutics in Q1 2021 and held it in 4 quarters.
  • Hudson Bay Capital Management's SAB Biotherapeutics position peaked at $5.04M in Q3 2021.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.